date:Oct 04, 2012
ase claims and that 7% lacked the disclaimer that is supposed to accompany every structure function claim.
The report went on to recommend that FDA should seek additional statutory authority to regulate label claims to make sure that suitable evidence exists to back up the claim, to make sure that proper label notifications are in place and to make sure companies are not making illegal disease claims. In addition, it said FDA needs to clean up its tracking of who is making what claims, and who